Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Bactiguard Holding AB's annualized net income for the quarter that ended in Mar. 2026 was kr-22.2 Mil. Bactiguard Holding AB's average shareholder tangible equity for the quarter that ended in Mar. 2026 was kr15.3 Mil. Therefore, Bactiguard Holding AB's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -145.32%.
The historical rank and industry rank for Bactiguard Holding AB's Return-on-Tangible-Equity or its related term are showing as below:
CHIX:BACTBs'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -343.87 Med: -219.34 Max: -49.44
Current: -279.25
During the past 13 years, Bactiguard Holding AB's highest Return-on-Tangible-Equity was -49.44%. The lowest was -343.87%. And the median was -219.34%.
CHIX:BACTBs's Return-on-Tangible-Equity is ranked worse than 94.85% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.08
vs CHIX:BACTBs: -279.25
Bactiguard Holding AB (CHIX:BACTBs) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Bactiguard Holding AB Return-on-Tangible-Equity Related Terms
Bactiguard Holding AB Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Bactiguard Holding AB's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bactiguard Holding AB Return-on-Tangible-Equity Chart
CHIX:BACTBS vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Bactiguard Holding AB's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bactiguard Holding AB Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bactiguard Holding AB's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Bactiguard Holding AB's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -145.32% mean?
Bactiguard Holding AB (CHIX:BACTBS) has a Return-on-Tangible-Equity of -145.32% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bactiguard Holding AB and its competitors. According to the industry distribution chart, Bactiguard Holding AB ranks #719 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 94.9%.
Is Bactiguard Holding AB's Return-on-Tangible-Equity too high?
Bactiguard Holding AB's current Return-on-Tangible-Equity is -145.32%. Based on the distribution chart, Bactiguard Holding AB ranks #719 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bactiguard Holding AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Bactiguard Holding AB's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Bactiguard Holding AB ranks #719 out of 758 companies for Return-on-Tangible-Equity. This places Bactiguard Holding AB in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Bactiguard Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bactiguard Holding AB's current Return-on-Tangible-Equity is -145.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bactiguard Holding AB stock overvalued right now?
Bactiguard Holding AB (CHIX:BACTBS) has a current Return-on-Tangible-Equity of -145.32%. The stock's GF Value™ is kr274.02, compared to a current price of kr128.60 — trading 53.1% below its estimated fair value. The current Return-on-Tangible-Equity is -145.32%. Bactiguard Holding AB's overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Bactiguard Holding AB (CHIX:BACTBS), the current Return-on-Tangible-Equity is -145.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bactiguard Holding AB (CHIX:BACTBS) Overvalued in 2026?
Based on GuruFocus' analysis, Bactiguard Holding AB stock appears to be undervalued.
The current stock price of kr128.60 is trading 53.1% below its estimated GF Value™ of kr274.02.
Key valuation signals for CHIX:BACTBS:
Return-on-Tangible-Equity: -145.32%
GF Value™: kr274.02 vs. price of kr128.60 (53.1% below fair value)
No single metric tells the full story. See the CHIX:BACTBS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bactiguard Holding AB is a medical device company. It is engaged in a MedTech company developing safe and biocompatible technology to prevent medical device-related infections. The technology is based on an ultra-thin noble metal coating that prevents bacterial adhesion and biofilm formation on medical devices. The company focuses on five strategic therapeutic areas wherein infection rates create high medical needs for infection prevention. These areas include Orthopedics, Cardiology, Neurology, Urology, and Vascular Access. Geographically, the company operates in the USA, Malaysia, China, Saudi Arabia, Bangladesh, Sweden, the Czech Republic, and Other countries. The majority of its revenue is generated from the USA region.
59GF Score
Get the complete analysis for CHIX:BACTBS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BACTBS has been successfully added to your 
